Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 26-Week Placebo-Controlled Efficacy and Safety Study of Mometasone Furoate/Formoterol Fumarate Combination Formulation Compared With Mometasone Furoate and Formoterol Monotherapy in Subjects With Persistent Asthma Previously Treated With Medium-Dose Inhaled Glucocorticosteroids
Brief Summary: This is a randomized, multi-center, double-blind, double-dummy, placebo-controlled, parallel-group study, evaluating the efficacy of mometasone furoate (MF) /formoterol fumarate (F)\[MF/F\] metered dose inhaler (MDI) versus MF for 26 weeks. Prior to the 26-week double-blind Treatment Period, subjects will receive open-label MF MDI 200 mcg twice daily (BID) for 2 to 3 weeks during the Run-in Period. Efficacy will be measured by The Area Under the Curve From 0 to 12 Hours \[AUC\](0-12 hours) of the Change From Baseline to the Week 12 Endpoint

in Forced Expiratory Volume in One Second (FEV1) \[Time Frame: Baseline to Week 12\] and Time-to-First Severe Asthma Exacerbation across the 26-week treatment period.


Options:
A: Arm Label: MF/F MDI 200/10 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID | Arm Label: MF MDI 200 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate MDI (MF MDI) 200 mcg | Arm Label: F MDI 10 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: formoterol fumarate 10 mcg | Arm Label: Placebo BID; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID; Assigned to Arm(s): MF/F MDI 200/10 mcg BID | Intervention Type: DRUG; Name: Mometasone furoate MDI (MF MDI) 200 mcg; Assigned to Arm(s): MF MDI 200 mcg BID | Intervention Type: DRUG; Name: formoterol fumarate 10 mcg; Assigned to Arm(s): F MDI 10 mcg BID | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo BID
B: Arm Label: CHF1535 NEXT DPI; Type: EXPERIMENTAL; Interventions: Drug: CHF1535 NEXT DPI | Arm Label: Free combination BDP and FF; Type: ACTIVE_COMPARATOR; Interventions: Drug: BDP DPI and formoterol DPI | Intervention Type: DRUG; Name: CHF1535 NEXT DPI; Assigned to Arm(s): CHF1535 NEXT DPI | Intervention Type: DRUG; Name: BDP DPI and formoterol DPI; Assigned to Arm(s): Free combination BDP and FF
C: Arm Label: 1 Symbicort/inhaler; Type: ACTIVE_COMPARATOR; Interventions: Drug: Symbicort | Arm Label: Symbicort/inhaler; Type: ACTIVE_COMPARATOR; Interventions: Drug: Symbicort | Arm Label: Budesonide/inhaler; Type: ACTIVE_COMPARATOR; Interventions: Drug: Budesonide | Intervention Type: DRUG; Name: Symbicort; Assigned to Arm(s): 1 Symbicort/inhaler | Intervention Type: DRUG; Name: Symbicort; Assigned to Arm(s): Symbicort/inhaler | Intervention Type: DRUG; Name: Budesonide; Assigned to Arm(s): Budesonide/inhaler
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone propionate/formoterol fumarate 100/10 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone propionate 100 | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol fumarate 10 | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fluticasone propionate/formoterol fumarate 100/10; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Fluticasone propionate 100; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Formoterol fumarate 10; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4

Answer: A